Monomethyl Fumarate
Fanconi Anemia
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 2/3Active
BBB
74/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Fanconi Anemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Porteus, Matthew, MD | Phase 2/3 | BBB |
Fludarabine Porteus, Matthew, MD | Phase 2/3 | BBB |
FILGRASTIM Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | BBB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | BBB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | BBB |
View all 43 →
Same molecule, other indications
Monomethyl Fumarate is also rated in:
Contiguous Stage II Adult Diffuse Small Cleaved Cell LymphomaDormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →